With a focus on improving patient outcomes through evidence-based healing solutions and services, Sanara MedTech Inc. markets and distributes wound and skin care products and is seeking to offer wound care and dermatology virtual consultation services via telemedicine to physicians, hospitals, clinics, and all post-acute care settings. Sanara's products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX® Surgical Activated Collagen® to the surgical markets as well as the following products to the wound care market:
BIAKŌS™ Antimicrobial Skin and Wound Cleanser, BIAKŌS™ Antimicrobial Wound Gel, BIAKŌS™ Antimicrobial Skin and Wound Irrigation Solution, and HYCOL™ Hydrolyzed Collagen Powder and Gel. The company is constantly seeking long-term strategic partnerships with a focus on products and technologies that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its six focus areas of wound and skin care for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy adjunct products, and the oxygen delivery system segment of the healthcare industry.
Company profile
Ticker
SMTI
Exchange
Website
CEO
J. Michael Carmena
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Avanos Medical • Edwards Lifesciences • MSA Safety • INVACARE • Align Technology • Surgalign ...
Former names
INAV TRAVEL CORPORATION, MB SOFTWARE CORP, WOUND MANAGEMENT TECHNOLOGIES, INC.
SEC CIK
Corporate docs
Subsidiaries
Cellerate, LLC • Wound Care Innovations, LLC • Sanara Biologics, LLC • Rochal Technologies, LLC • WounDerm, LLC • United Wound and Skin Solutions, LLC • Precision Healing, LLC • Scendia Biologics, LLC ...
IRS number
592220004
SMTI stock data
Latest filings (excl ownership)
8-K
Sanara MedTech Inc. Announces First Quarter 2023 Results
15 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
ARS
2022 FY
Annual report to shareholders
21 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
8-K
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 Results
20 Mar 23
10-K
2022 FY
Annual report
20 Mar 23
8-K
Entry into a Material Definitive Agreement
24 Feb 23
424B5
Prospectus supplement for primary offering
24 Feb 23
Transcripts
SMTI
Earnings call transcript
2023 Q1
16 May 23
SMTI
Earnings call transcript
2022 Q4
21 Mar 23
SMTI
Earnings call transcript
2022 Q3
15 Nov 22
SMTI
Earnings call transcript
2022 Q2
16 Aug 22
SMTI
Earnings call transcript
2022 Q1
17 May 22
SMTI
Earnings call transcript
2021 Q4
31 Mar 22
SMTI
Earnings call transcript
2021 Q3
15 Nov 21
SMTI
Earnings call transcript
2021 Q2
17 Aug 21
Latest ownership filings
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 7.29 mm | 7.29 mm | 7.29 mm | 7.29 mm | 7.29 mm | 7.29 mm |
| Cash burn (monthly) | 557.52 k | 738.05 k | 405.44 k | 994.46 k | 580.44 k | 431.98 k |
| Cash used (since last report) | 1.11 mm | 1.47 mm | 805.46 k | 1.98 mm | 1.15 mm | 858.17 k |
| Cash remaining | 6.18 mm | 5.82 mm | 6.48 mm | 5.31 mm | 6.13 mm | 6.43 mm |
| Runway (months of cash) | 11.1 | 7.9 | 16.0 | 5.3 | 10.6 | 14.9 |
Institutional ownership, Q4 2022
4.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 31 |
| Opened positions | 9 |
| Closed positions | 4 |
| Increased positions | 9 |
| Reduced positions | 5 |
| 13F shares | Current |
|---|---|
| Total value | 14.70 bn |
| Total shares | 381.84 k |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 96.06 k | $4.37 bn |
| EAM Investors | 54.76 k | $2.49 bn |
| Geode Capital Management | 28.11 k | $1.28 mm |
| Diametric Capital | 24.89 k | $1.13 bn |
| North Run Capital L P | 24.00 k | $1.09 bn |
| Susquehanna International | 15.23 k | $692.83 mm |
| AMP Ameriprise Financial | 13.85 k | $629.00 mm |
| Citadel Advisors | 12.57 k | $571.94 mm |
| Salem Investment Counselors | 11.21 k | $510.06 mm |
| Bamco | 10.71 k | $487.08 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 12 Apr 23 | Michael D. McNeil | Common Stock | Option exercise | Acquire M | No | No | 6 | 1,000 | 6.00 k | 23,025 |
| 12 Apr 23 | Michael D. McNeil | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 6 | 1,000 | 6.00 k | 0 |
| 17 Mar 23 | Rebecca E McMahon | Common Stock | Payment of exercise | Dispose F | No | No | 41.5 | 201 | 8.34 k | 9,595 |
| 17 Mar 23 | Michael D. McNeil | Common Stock | Payment of exercise | Dispose F | No | No | 41.5 | 532 | 22.08 k | 22,025 |
| 17 Mar 23 | Michael D. McNeil | Common Stock | Payment of exercise | Dispose F | No | No | 43.3 | 253 | 10.95 k | 22,557 |
| 17 Mar 23 | Michael D. McNeil | Common Stock | Payment of exercise | Dispose F | No | No | 40.5 | 658 | 26.65 k | 22,810 |
| 17 Mar 23 | Fleming Zachary B. | Common Stock | Payment of exercise | Dispose F | No | No | 41.5 | 717 | 29.76 k | 40,243 |
| 17 Mar 23 | Fleming Zachary B. | Common Stock | Payment of exercise | Dispose F | No | No | 43.3 | 325 | 14.07 k | 40,960 |
| 17 Mar 23 | Fleming Zachary B. | Common Stock | Payment of exercise | Dispose F | No | No | 40.5 | 812 | 32.89 k | 41,285 |
| 17 Mar 23 | Fleming Zachary B. | Common Stock | Payment of exercise | Dispose F | No | No | 40.5 | 1,101 | 44.59 k | 42,097 |
Press releases
Sanara MedTech Inc. Announces First Quarter 2023 Results
15 May 23
Sanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call Dates
3 May 23
Sanara MedTech Inc. Announces 510(k) Clearance for BIASURGE™ Advanced Surgical Solution
4 Apr 23
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 Results
20 Mar 23